Evidence map›Paper›PMID 28674539›Full record

ArticleFrontiers in immunology2017

Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.

Arwen Stikvoort, Yang Chen, Emelie Rådestad, Johan Törlén, Tadepally Lakshmikanth, Andreas Björklund, Jaromir Mikes, Adnane Achour, Jens Gertow, Berit Sundberg and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03885713 (Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03885713 phase4completednot on this mapstarted 2019, after this paper: background citation

Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches

TypeinterventionalSponsorFundación de Investigación Biomédica - Hospital Universitario de La PrincesaRan2019 to 2024Enrolled180ConditionsInflammatory Bowel Diseases, Crohn Disease, Ulcerative ColitisArmsInfliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. MAIT cells and their implication in human oral diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Biomarkers for Allogeneic HCT Outcomes.Frontiers in immunology · 2020
    Review
  16. T-cell frequencies of CD8Bone marrow transplantation · 2019
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Arwen StikvoortDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Yang ChenScience for Life Laboratory, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Emelie RådestadDepartment of Clinical Sciences, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden.
Johan TörlénDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Tadepally LakshmikanthScience for Life Laboratory, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Andreas BjörklundDepartment of Medicine, Karolinska Institute, Stockholm, Sweden.
Jaromir MikesScience for Life Laboratory, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Adnane AchourScience for Life Laboratory, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Jens GertowCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital, Stockholm, Sweden.
Berit SundbergDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Mats RembergerCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital, Stockholm, Sweden.
Mikael SundinDepartment of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Huddinge, Sweden.
Jonas MattssonDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Petter BrodinScience for Life Laboratory, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Michael UhlinDepartment of Clinical Sciences, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SEScience for Life Laboratory · SEKTH Royal Institute of Technology · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic graft-versus-host disease (cGVHD) is a debilitating complication arising in around half of all patients treated with an allogeneic hematopoietic stem cell transplantation. Even though treatment of severe cGVHD has improved during recent years, it remains one of the main causes of morbidity and mortality in affected patients. Biomarkers in blood that could aid in the diagnosis and classification of cGVHD severity are needed for the development of novel treatment strategies that can alleviate symptoms and reduce the need for painful and sometimes complicated tissue biopsies. Methods that comprehensively profile complex biological systems such as the immune system can reveal unanticipated markers when used with the appropriate methods of data analysis. Here, we used mass cytometry, flow cytometry, enzyme-linked immunosorbent assay, and multiplex assays to systematically profile immune cell populations in 68 patients with varying grades of cGVHD. We identified multiple subpopulations across T, B, and NK-cell lineages that distinguished patients with cGVHD from those without cGVHD and which were associated in varying ways with severity of cGVHD. Specifically, initial flow cytometry demonstrated that patients with more severe cGVHD had lower mucosal-associated T cell frequencies, with a concomitant higher level of CD38 expression on T cells. Mass cytometry could identify unique subpopulations specific for cGVHD severity albeit with some seemingly conflicting results. For instance, patients with severe cGVHD had an increased frequency of activated B cells compared to patients with moderate cGVHD while activated B cells were found at a reduced frequency in patients with mild cGVHD compared to patients without cGVHD. Moreover, results indicate it may be possible to validate mass cytometry results with clinically viable, smaller flow cytometry panels. Finally, no differences in levels of blood soluble markers could be identified, with the exception for the semi-soluble combined marker B-cell activating factor/B cell ratio, which was increased in patients with mild cGVHD compared to patients without cGVHD. These findings suggest that interdependencies between such perturbed subpopulations of cells play a role in cGVHD pathogenesis and can serve as future diagnostic and therapeutic targets.

Indexed as

flow cytometrygraft-versus-host diseasehematopoietic stem cell transplantationimmunophenotypingmass cytometry

Identifiers

PMID28674539
PMCPMC5474470
OpenAlexW2624819889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.